Giving first glimpse of data, Scancell looks for Covid-19 vaccine partner
UK-based biotech Scancell is lifting the veil off a Phase I trial for its Covid-19 vaccine, but it’ll also be making a pivot on the vaccine’s strategy.
Scancell said in a release on Monday that it is presenting the preliminary data from its Phase I clinical trial, which was conducted at the University of Cape Town Lung Institue in South Africa. The trial was intended to look at two of vaccine Scancell’s candidates, SCOV1 and SCOV2, in patients before testing them as a booster. According to the biotech, both candidates are plasmid DNA-based vaccines.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.